>> JUNE AS NESSA NATIONAL MEN’S HEALTH MONTH AND FACING A BIG PROBLEM FOR MANY MEN IS
THEY JUST REFUSE. THEY DON’T
GO TO THE DOCTOR. THINKING IS
IF I DON’T KNOW ABOUT IT, IT
AIN’T GOING TO HAPPEN TO ME.
WELL, WRONG DON’T MEAN TO BE
CLICHE HERE, BUT BETTER SAFE
THAN SORRY. SO THIS MONTH
WE’LL TAKE A LOOK AT A VARIETY
OF MEN’S HEALTH ISSUES IN
TODAY. THE FOCUS IS ON
PROSTATE CANCER. IT IS THE
MOST COMMON NON SKIN CANCER IN
THE U.S. AND IT IS PRETTY
PREVALENT AFFECTING ONE IN
EVERY 6 OR 7 MEN. JOINING ME
ON THE MORNING SHOW, DOCTOR
BECAUSE RYAN, A FELLOWSHIP
TRAINED UROLOGIST WITH BECAUSE
RYAN UROLOGY HERE IN
JACKSONVILLE. GOOD MORNING
MORNING. SO THERE HAVE AN
ADVISORY THAT CAME OUT. MAYBE
WE SHOULDN’T HAVE AS ACTIVE
SURVEILLANCE, BUT THEN
SOMETHING HAPPENED.
>> YES. SO IF YOU LOOK 2008,
2012.
>> THERE’S A RECOMMENDATION
PROSTATE CANCER SCREENING. AND
AND WHAT WE FOUND, YOU KNOW,
NOT SURPRISINGLY SCREENING
NUMBERS WENT DOWN AND STUDIES
HAVE COME OUT SHOWING THAT THE
RATES OF METASTATIC PROSTATE
CANCER, WHICH IS A REALLY THE
REASON WHY WE SCREEN, YOU
KNOW, PROSTATE CANCER CAN FIND
HERE. PROSTATE IS AND WHAT WE
WORRY ABOUT. WE TREATED TO
AVOID METASTATIC PROSTATE
CANCER, WHICH UNFORTUNATELY IS
SOMETHING THEY COULD
POTENTIALLY BECOME REALLY
DEBILITATING TO YOUR QUALITY
OF LIFE, BUT ALSO CAN IMPACT
THE QUANTITY OF YOUR LIFE. IT
CAN BE FATAL. SO THAT OPENS
THE CONVERSATION AGAIN OF THE
IMPORTANCE OF TALKING TO YOUR
DOCTOR ABOUT SCREENING FOR
PROSTATE CANCER, WHICH
INVOLVES A SIMPLE LAB TEST,
CALLED A PSA TEST AND ALSO A
RECTAL EXAM. AND THERE ARE
RARELY, IF ANY EARLY WARNING
SIGNS. BUT THERE ARE SOME
SIGNS THAT DO POP UP
OCCASIONALLY THAT LET YOU
MAYBE I SHOULD GET THIS
CHECKED OUT. YOU KNOW, THE END
OF THE THINGS TO THINK ABOUT
MOST MEN ARE GOING TO HAVE
DIFFICULTIES WITH TO BE
MINDFUL. THOSE ARE USUALLY
RELATED TO DIFFICULTIES WITH
URINATION. NEW TO BPH, A
BENIGN ENLARGEMENT OF THE
PROSTATE. HOWEVER, TAKE IT AS
AN OPPORTUNITY, WHETHER IT’S
YOU OR WHETHER SOMEONE YOU
LOVE EXPERIENCING THOSE. IT GO
TALK TO YOUR DOCTOR. GETTING A
PSA IS A SIMPLE TEST THAT CAN
THEY CAN HIGHLIGHT SOMETHING
THAT IS VERY, VERY BEGINNING
STAGES FOR PROSTATE CANCER,
CONFINED TO THE PROSTATE IS
VERY, VERY TREATABLE. AND NOW
WE HAVE A LOT OF LOT OF VERY,
VERY EFFECTIVE WAYS OF
TREATING IT THAT ARE
PRESERVING A QUALITY OF LIFE,
BUT ALSO VERY CURATIVE
APPROACHING. 95 THE 100%. ONE
OF THOSE TREATMENTS IS
ACTUALLY ACTIVE SURVEILLANCE,
ACTIVE SURVEILLANCE, NOT ALL
PROSTATE CANCER. THIS
DIAGNOSED NEEDS TO BE TREATED
A 40 TO 50% OF THE PROSTATE
CANCERS WE DIAGNOSE OR VERY
LOW VOLUME, VERY LOW RISK. AND
YOU CAN MONITOR IT WITH
FREQUENT PSA CHECKS, RECTAL
EXAMS AND REPEAT BIOPSIES. SO
WE WE MONITOR THE PROGRESSION
OF THE DISEASE, WHICH IS VERY
SLOW IN THOSE CASES. AND IT’S
NOT A FATAL DISEASE. WE CAN
TREAT MORE OF A CHRONIC
DISEASE. SO THE IMPACT ON THE
QUALITY OF YOUR LIFE IS
MINIMAL. WE AVOID MISSING
THOSE CANCERS THAT COULD
CHANGE AND CAUSE YOU TO PASS
AWAY FROM THE DISEASE. SO USED
TO BE YOU CAN DO A. WE REMOVE
THE PROSTATE, BUT NOW YOU
DON’T HAVE TO NECESSARILY MOVE
THE ENTIRE FRONT. WE HAVE SO
MANY DIFFERENT OPTIONS WHEN
YOU ACTUALLY GET DIAGNOSED
WITH PROSTATE CANCER, EVEN
THINGS LIKE FOCAL THERAPY. NOW
WE DO SMARTER BY PATHWAYS,
WHICH INCLUDE MRI SCANS AND
THAT IF WE FIND IT HARD TO
BELIEVE WE CAN DO A FUSION
BIOPSY IS CALLED. WE TAKE THE
MRI ON MERGING THE IMAGES
TOGETHER AND TARGET THAT AREA.
THAT’S THE ONLY AREA THAT YOU
HAVE CANCER WE CAN DO FOCAL
THERAPY WHERE WE JUST TREAT
THE PORTION OF THE PROCESS
THAT HAS THE CANCER LEAVE THE
UNAFFECTED TISSUE ALONE. SO
THE MORE PROSTATE YOU PRESERVE
THEM OR FUNCTION, YOU
PRESERVE. SO THEREBY YOU TAKE
CARE OF THE CANCER, BUT YOU
ALSO TAKE CARE OF THE QUALITY
OF LIFE ISSUES THAT MOST
PEOPLE USE AS POTENTIALLY AN
EXCUSE IN THEIR MIND TO AVOID
SCREENING IN THE FIRST PLACE.
AND THEY RECENTLY DID A
CLINICAL STUDY AND THEY FOUND
A FAIRLY GOOD OPTION FOR
TREATING IT. AND IT’S GOT A
PRETTY GOOD OUTCOME OVER 5
YEARS. SO IF YOU LOOK, THERE
ARE A NUMBER OF DIFFERENT
OPTIONS TO THINK ABOUT ONE.
YOU HAVE ACTIVE SURVEILLANCE
TO THE PROCESS. TO ME IS IS IS
BETTER IN TERMS OF THE
PRESERVATION OF QUALITY OF
LIFE WITH A ROBOTIC
TECHNOLOGY, THE FOCAL THERAPY
OPTIONS. WE HAVE HIGH
INTENSITY FOCUSED ULTRASOUND.
THERE ARE A NUMBER OF
DIFFERENT OPTIONS THAT ARE
THAT ARE FOCAL EOP AVAILABLE
THAT ARE ARE GOOD, GOOD
OPTIONS IN TERMS OF THE
BALANCE OF CURE AND THE SIDE
EFFECT PROFILE AND THEN
RADIATION THERAPY OPTIONS ARE
NOW MORE PRECISE THAT THIS
STUDY ARE ALLUDING TO EVEN
TALK ABOUT IF MEN WHO UNDERGO
A PROCESS THAT TEXTING ME AND
HAVE RECURRENCE IS NOW CAN GET
A VERY, VERY FOCAL RADIATION
THERAPY TO NOT ONLY THE BETTER
FOR THE PROSTATE WAS WAS
REMOVED, BUT ALSO INCLUDE THE
RADIATION BED TO INCLUDE THE
PELVIS AND AND AND AGAIN,
HARMON BLOCKADE THERAPIES AND
THOSE MEN GOT UP TO 90% CURE
RATE UP TO 5 YEARS. SO THIS IS
IDEA OF LOOKING AT THE
TOTALITY OF CARE OF THE
PROSTATE CANCER FROM THE
BEGINNING TO THE END OF
DISEASE. WHEN WE TALK ABOUT
THAT, EVEN ADVANCED PROSTATE
CANCER, THIS WE’VE GONE BEYOND
THE PROSTATE. NOW WE LOOK AT
IT’S NOT JUST THE IDEA. WE
GIVE THEM BLOCKING
TESTOSTERONE LEVELS. WE CAN
TARGET LESIONS. WE HAVE BETTER
AND IMAGING STUDIES THAT LOOK
FOR TARGET ABUL LESIONS. SO
THEN WE HAVE BETTER
MEDICATIONS OR EVEN BILLS THAT
WE CAN TAKE. SO THE WHOLE
PATHWAY HAS CHANGED TO BE MORE
PRECISE, MORE ACCURATE, MORE
TARGETED. BUT IT ALL STARTS
WITH SCREENING. SO WE DON’T
EVEN HAVE TO GET TO THOSE
CONVERSATIONS. SO THE BOTTOM
LINE IS CATCH IT EARLY. BETTER
CLINICAL OUTCOMES. AND WHEN
YOU THINK ABOUT PROSTATE
CANCER, IT’S NOT THE OUTCOME